BREAKING
Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 2 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 4 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 5 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 5 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 6 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 8 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 8 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 9 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 9 hours ago Innovation and E-Commerce at the Core of Johnson Outdoors’ 2026 Roadmap 9 hours ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 2 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 4 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 5 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 5 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 6 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 8 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 8 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 9 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 9 hours ago Innovation and E-Commerce at the Core of Johnson Outdoors’ 2026 Roadmap 9 hours ago
ADVERTISEMENT
AlphaGraphs

Wider-than-expected Q2 loss sends Tilray stock lower

Tilray (NASDAQ: TLRY) reported a loss of 32 cents per share in the second quarter, more than double what it reported last year, as rising operating expenses continue to weigh on its bottom-line. This was wider than analysts’ projection of a loss of 25 cents per share. Revenue came in at $45.9 million, up 371% […]

August 13, 2019 2 min read

Tilray (NASDAQ: TLRY) reported a loss of 32 cents per share in the second quarter, more than double what it reported last year, as rising operating expenses continue to weigh on its bottom-line. This was wider than analysts’ projection of a loss of 25 cents per share.

Revenue came in at $45.9 million, up 371% year-over-year and above analysts’ prediction of $41.1 million, driven by the Manitoba Harvest acquisition, the legalization of the Canadian adult-use market, and growth in Europe.

tilray q2 2019 earnings results

Total kilogram equivalents sold tripled to 5,588 kilograms from 1,514 kilograms in the prior-year period. However, the average net selling price per gram decreased to $4.61 from $6.38 a year ago.

TLRY shares were down 5.9% immediately following the announcement. The stock has tumbled 80% since its IPO last year. However, it has stabilized from April, trading mostly between $40 and $50.

Gross margin increased sequentially to 27% from 23% in the prior quarter.

ADVERTISEMENT
cannabis stocks performance comparison

Though Tilray has put in a considerable amount of investments
into beverage and retail partnerships, there is rising criticism that even
these initiatives are overvalued in the markets. It’s hard to be sure though,
given we are at the early stages of the cannabis industry.

As Tilray trailed behind its rivals in the medical marijuana segment, it shifted its focus to the abundant opportunities in the CBD-infused food products industry. The acquisition of Manitoba Harvest and more recently, UK-based alcohol gummy maker Smith & Sinclair, were aimed at producing food products based on cannabinoid.

READ: Canopy Growth earnings preview: Q1 crucial in the recent turn of events

In Q2, revenue from Food Products segment grew to $19.9 million, representing almost 43% of total revenues.

cannabis stocks market cap comparison; Canopy Growth, Aurora Cannabis, GW pharmaceuticals, Cronos Group, Tilray, Aphria, Hexo, Village Farms

However, the Federal Drug Administration recently questioned
the authenticity and safety aspects of such products, besides initiating the
first hearing on it two weeks ago.

ADVERTISEMENT

Rival Aurora Cannabis (NYSE: ACB) will report earnings results on August 20, while Canopy
Growth (NYSE: CGC) will report on August 14.  

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

ADVERTISEMENT